At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Valproic Acid +1 moredrug
Likely dose
Valproic Acid 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa
In Brief
A Phase 2 clinical trial evaluating Valproic Acid and Placebo for Retinitis Pigmentosa. Completed, enrolled 90 participants across 6 sites.
Detailed Summary
The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionDec 2015
TodayJul 2026
First PostedNov 3, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 15.7 years ago
Interventions
Valproic Aciddrug
One to four 250mg softgels by mouth daily (dose determined by body weight)
Placebodrug
Dosage per subject weight- same schedule as the active comparator